HROW Stock Overview
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Harrow, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$10.27 |
| 52 Week High | US$28.25 |
| 52 Week Low | US$7.60 |
| Beta | 0.50 |
| 1 Month Change | -14.42% |
| 3 Month Change | 6.31% |
| 1 Year Change | -58.74% |
| 3 Year Change | 27.42% |
| 5 Year Change | 125.71% |
| Change since IPO | 18.75% |
Recent News & Updates
Recent updates
Harrow's Drug Iheezo Is Off To A Great Start
Feb 19Harrow: Temporary Disruption In Stock Price Creates Excellent Opportunity
Jan 30Harrow sells non‑ophthalmic compounding business, terms undisclosed
Oct 05Harrow Health soars ~27% on FDA nod of anesthesia gel for the surface of the eye
Sep 27SRK Capital - Harrow Health: Market Missing The Forest For The Trees
Aug 19These 4 Measures Indicate That Harrow Health (NASDAQ:HROW) Is Using Debt Extensively
Aug 11
Buy Deep Moated, Fast Growing, Superbly Managed Harrow Health Ahead Of New Product Launch
May 23Does Harrow Health (NASDAQ:HROW) Have A Healthy Balance Sheet?
May 12Is Harrow Health (NASDAQ:HROW) A Risky Investment?
Dec 15Does Harrow Health (NASDAQ:HROW) Have A Healthy Balance Sheet?
Aug 24Harrow Health prices 8.625% senior notes due 2026
Jun 15Harrow Health: An 8.3% Baby Bond Yield With Low Balance Sheet Leverage
May 28Shareholders Shouldn’t Be Too Comfortable With Harrow Health's (NASDAQ:HROW) Strong Earnings
May 18Harrow Health, Inc. (NASDAQ:HROW) Just Reported And Analysts Have Been Lifting Their Price Targets
Mar 11Announcing: Harrow Health (NASDAQ:HROW) Stock Increased An Energizing 299% In The Last Three Years
Mar 08Is Harrow Health (NASDAQ:HROW) Using Debt Sensibly?
Feb 01
Shareholder Returns
| HROW | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -13.1% | 0.08% | 1.2% |
| 1Y | -58.7% | 13.2% | 24.9% |
Return vs Industry: HROW underperformed the US Pharmaceuticals industry which returned 13.9% over the past year.
Return vs Market: HROW underperformed the US Market which returned 24.7% over the past year.
Price Volatility
| HROW volatility | |
|---|---|
| HROW Average Weekly Movement | 7.9% |
| Pharmaceuticals Industry Average Movement | 9.8% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: HROW's share price has been volatile over the past 3 months.
Volatility Over Time: HROW's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 315 | Mark Baum | www.harrow.com |
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract surgery; VIGAMOX, a fluoroquinolone antibiotic eye drop for the treatment of bacterial conjunctivitis; MAXIDEX and FLAREX, a steroid eye drop for steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe and the eye; TRIESENCE, a steroid injection for the treatment of ophthalmic diseases and for visualization during vitrectomy; and NATACYN, a sterile, antifungal drug for the treatment of fungal blepharitis, conjunctivitis, and keratitis.
Harrow, Inc. Fundamentals Summary
| HROW fundamental statistics | |
|---|---|
| Market cap | US$364.94m |
| Earnings (TTM) | -US$24.41m |
| Revenue (TTM) | US$130.19m |
2.8x
P/S Ratio-14.9x
P/E RatioIs HROW overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HROW income statement (TTM) | |
|---|---|
| Revenue | US$130.19m |
| Cost of Revenue | US$39.64m |
| Gross Profit | US$90.55m |
| Other Expenses | US$114.96m |
| Earnings | -US$24.41m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.69 |
| Gross Margin | 69.55% |
| Net Profit Margin | -18.75% |
| Debt/Equity Ratio | 260.1% |
How did HROW perform over the long term?
See historical performance and comparison